SCHEMBL4424052

SCHEMBL4424052

CCOC(=O)C(C)(C)Oc1cc(O)c2ccccc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 4/20 0.51
CYP1A2 P05177 2/20 0.51
CYP3A4 P08684 2/20 0.51
ABCB11 O95342 1/20 0.51
TSHR P16473 1/20 0.51
HTR2A P28223 1/20 0.51
PMP22 Q01453 1/20 0.51
PPARG P37231 3/20 0.48
FBP1 P09467 9/20 0.47
CDC25B P30305 2/20 0.43
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
RECQL P46063 1/20 0.41
KMT2A Q03164 1/20 0.41
NQO2 P16083 1/20 0.41
CDC25A P30304 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4431085 0.82 FBP1 (0.46) PPARACYP1A2CYP3A4ABCB11TSHR
SCHEMBL7768542 0.78 NQO2 (0.46) CYP1A2CYP3A4CDC25BMEN1NPC1
Phenol SCHEMBL4706535 0.77 PPARA (0.63) PPARACYP1A2CYP3A4ABCB11TSHR
SCHEMBL197882 0.77 PPARA (0.64) PPARACYP1A2CYP3A4ABCB11TSHR
SCHEMBL2824491 0.77 PPARA (0.71) PPARACYP1A2CYP3A4ABCB11TSHR
SCHEMBL6035075 0.76 PPARA (0.61) PPARACYP1A2CYP3A4ABCB11TSHR
SCHEMBL4421092 0.76 FBP1 (0.44) PPARACYP1A2CYP3A4ABCB11TSHR
SCHEMBL17323584 0.76 NQO2 (0.44) PPARACYP1A2CYP3A4PPARGCDC25B
SCHEMBL199420 0.75 PPARA (0.73) PPARACYP1A2CYP3A4ABCB11TSHR
SCHEMBL6036068 0.75 PPARA (0.60) PPARACYP1A2CYP3A4ABCB11TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495001-B2 Benzannelated derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2009-02-24 US disclosed
EP-1682507-A1 BENZANNELATED COMPOUNDS AS PPAR ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2006-07-26 EP disclosed
WO-2005049572-A1 BENZANNELATED COMPOUNDS AS PPAR ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2005-06-02 WO disclosed
US-20050096336-A1 Benzannelated derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096336-A1 Benzannelated derivatives, their manufacture and use as pharmaceutical agents PPARD, PPARA, PPARG PPARA 2/4885CYP1A2 153/4885CYP3A4 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.